Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

NCT07168200 is registered in ClinicalTrials.gov with Shanghai Shengdi Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07168200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07168200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Lead sponsor
Shanghai Shengdi Pharmaceutical Co., Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
October 17, 2025
Completion date
December 31, 2028
Enrollment
720 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cervical cancer